pTau blood test to assess cognitive decline
The pTau blood test measures the phosphorylated tau proteinA biomarker associated with neurodegenerative processes. It is a simple test that can help assess whether there are alterations consistent with early cognitive decline, always within the context of a complete clinical study.
We call you
Error: Contact form not found.
Biomarker related to neurodegenerative processes.
Convenient test using blood analysis.
It can detect changes associated with early cognitive decline.
Useful as support in neurological assessment.
Clear report to discuss with your doctor or neurologist.
What is the pTau analysis?
The pTau test measures in the blood the phosphorylated tau protein, an altered form of the tau protein that has been associated with neurodegenerative diseases, including Alzheimer's disease.
Although it is not useful for diagnosis on its own, this biomarker can provide relevant information when there are cognitive symptoms, background or doubts about the origin of a recent deterioration.
This study is also known as:
- pTau blood biomarker
- Analysis of phosphorylated tau protein
- pTau-217
Who is this analysis intended for?
The pTau test can be useful if:
✓ You present memory loss, disorientation or cognitive changes.
✓ You have a family history of neurodegenerative diseases.
✓ A specialist has suggested expanding the study of cognitive impairment.
✓ Do you want a trial? less invasive technique that the analysis in cerebrospinal fluid (CSF).
✓ You are starting a neurological evaluation process and need supporting biomarkers.
It should always be interpreted by a doctor or neurologist.
What exactly does the pTau test analyze?
The analysis includes:
1. Measurement of phosphorylated tau protein (pTau-217)
pTau-217 is a biomarker used to assess neurodegenerative processes. Elevated levels may be associated with neurological disorders and should be evaluated by a specialist.
2. Possible association with cognitive impairment
pTau levels can help assess whether there is a pattern consistent with early alterations.
3. Indicative value
It is a complementary biomarker that should be interpreted in conjunction with other clinical and imaging tests.
Benefits of having this analysis done
The analysis includes:
Quick and affordable test
It is carried out through a simple blood draw.
Early information
It can detect alterations associated with cognitive decline before advanced stages.
Complement to neurological assessment
It helps specialists guide the study in people with symptoms.
Less invasive alternative
It may be a preliminary step to more complex tests such as lumbar puncture.
Clear and informative report
Facilitate the conversation with your neurologist or primary care physician.
How is the test performed?
Step 1:
Request the test
Visit your Ribera Lab center to get tested.
Step 2:
Sample collection
A blood sample is taken. No fasting or prior preparation is required.
Step 3:
Laboratory analysis
The concentration of phosphorylated tau protein in the sample is measured.
Step 4:
Results report
You will receive a clear report with your pTau levels to discuss with your doctor or neurologist.
Interpretation of results
Elevated pTau levels
They may be associated with neurodegenerative changes. They do not confirm disease on their own.
Levels within the expected range
They reduce the likelihood of detectable impairment, but do not rule out all causes of cognitive decline.
Joint clinical interpretation
The result should be considered in conjunction with:
- symptom
- clinic history
- imaging tests
- neuropsychological tests